Effect of Saffron in Metabolic Syndrome

Phase 2

• Conditions: Metabolic Syndrome.; Metabolic syndrome; E88.81

• Registration Number: IRCT20110726007117N10
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

18–75 years old
Patients with Metabolic Syndrome according to the International Diabetic Federation criteria

Exclusion Criteria

Systemic diseases such as lupus, kidney disease, acquired immunodeficiency syndrome and rheumatoid arthritis
Pregnant and lactating women
Drug usage including consumption of the lipid-lowering, antihypertensive and antidiabetic drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anti-Heat Shock Protein titre. Timepoint: Before the intervention and 12 weeks after taking drug or placebo. Method of measurement: Enzyme Linked Immunosorbent Assay.;Pro-Oxidant–Antioxidant Balance. Timepoint: Before the intervention and 12 weeks after taking drug or placebo. Method of measurement: Enzyme Linked Immunosorbent Assay.;Superoxide Dismutase. Timepoint: Before the intervention and 12 weeks after taking drug or placebo. Method of measurement: Spectrophotometry.

Secondary Outcome Measures

Name	Time	Method
Serum Copper. Timepoint: Before the intervention and 12 weeks after taking drug or placebo. Method of measurement: Atomic Absorption.;Serum Zinc. Timepoint: Before the intervention and 12 weeks after taking drug or placebo. Method of measurement: Atomic Absorption.